Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298229 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT04298229 is a Phase 3 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 240 participants.
The verdict
NCT04298229, a Phase 3 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a randomized trial of the addition of dapagliflozin to patients with or without type 2 diabetes hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy or dapagliflozin + protocolized diuretic therapy.
Interventions
- DRUG Dapagliflozin 10 MG
- OTHER Protocolized Diuretic Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298229
The ClinicalTrials.gov registry entry for NCT04298229 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin 10 MG is the first listed.
NCT04298229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04298229 about?
NCT04298229 is a clinical study titled "Efficacy and Safety of Dapagliflozin in Acute Heart Failure". This is a randomized trial of the addition of dapagliflozin to patients with or without type 2 diabetes hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADH...
What is the current status of trial NCT04298229?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2020-04-01. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT04298229?
The interventions under investigation include: Dapagliflozin 10 MG (DRUG), Protocolized Diuretic Therapy (OTHER).
Who is sponsoring clinical trial NCT04298229?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.